We are excited to have all our submitted presentations and posters be accepted! If attending the American Chemical Society come see us…

Lentiviral vectors (LVs) are widely used viral vectors necessary for the production of several commercial cell and gene therapies. However, their innate fragility and cytotoxicity, due to their lipid bilayer and VSVG (vesicular stomatitis virus envelope glycoprotein) pseudotype, respectively, means that the manufacturing cost of these vectors is extremely high. Traditional downstream purification strategies are being commercially adapted for large and complex viruses.

This interview features: Kelli Luginbuhl, Founder, Business Leader, Isolere Bio by Donaldson, from BioProcess International 2023.

MINNEAPOLIS (February 21, 2023) — Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, today announced the acquisition of (Isolere), an early-stage biotechnology company that develops novel and proprietary IsoTag™ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

Adeno-associated viruses (AAV) have high potential for use as a gene therapy vehicle because of their superior safety profile, but low expression titers, shockingly inefficient purification, and increasingly scrutinized regulatory requirements are slowing development and casting doubt on its commercial feasibility.

Isolere enters into an agreement with Oxford Biomedica to develop next-generation manufacturing solutions for lentiviral vectors.

Isolere Bio receives a Phase I SBIR award from NIH to support application of the IsoTag technology to lentivirus manufacturing